140 related articles for article (PubMed ID: 25916436)
1. Detection of small abnormal B-Lymphoblast populations at diagnosis of chronic myelogenous leukemia, BCR-ABL1+: Incidence, phenotypic features, and clinical implications.
Vrotsos E; Gorgan M; DiGiuseppe JA
Cytometry B Clin Cytom; 2017 Jul; 92(4):275-278. PubMed ID: 25916436
[TBL] [Abstract][Full Text] [Related]
2. Small, abnormal B lymphoid blast populations in chronic myelogenous leukemia at diagnosis: Does this finding indicate an accelerated course?
Soma L; Oehler VG; Ding C; Cherian S
Cytometry B Clin Cytom; 2016 Sep; 90(5):440-8. PubMed ID: 26800237
[TBL] [Abstract][Full Text] [Related]
3. [Differential analysis of BM cell morphology, immunophenotypic, cytogenetic characters and prognosis between myeloblastic and lymphoblastic crisis of CML].
Liu YL; Wang XN; Liu HS
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2014 Jun; 22(3):629-33. PubMed ID: 24989266
[TBL] [Abstract][Full Text] [Related]
4. Dasatinib: a tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia and philadelphia chromosome-positive acute lymphoblastic leukemia.
Steinberg M
Clin Ther; 2007 Nov; 29(11):2289-308. PubMed ID: 18158072
[TBL] [Abstract][Full Text] [Related]
5. The immunophenotype of blast transformation of chronic myelogenous leukemia: a high frequency of mixed lineage phenotype in "lymphoid" blasts and A comparison of morphologic, immunophenotypic, and molecular findings.
Khalidi HS; Brynes RK; Medeiros LJ; Chang KL; Slovak ML; Snyder DS; Arber DA
Mod Pathol; 1998 Dec; 11(12):1211-21. PubMed ID: 9872654
[TBL] [Abstract][Full Text] [Related]
6. Early BCR-ABL1 Reduction Is Predictive of Better Event-free Survival in Patients With Newly Diagnosed Chronic Myeloid Leukemia Treated With Any Tyrosine Kinase Inhibitor.
Fava C; Rege-Cambrin G; Dogliotti I; Gottardi E; Berchialla P; Di Gioacchino B; Crasto F; Lorenzatti R; Volpengo A; Daraio F; Fantino C; Saglio G
Clin Lymphoma Myeloma Leuk; 2016 Aug; 16 Suppl():S96-S100. PubMed ID: 27131622
[TBL] [Abstract][Full Text] [Related]
7. Sudden blast phase in pediatric chronic myeloid leukemia-chronic phase with abnormal lymphoid blasts detected by flow cytometry at diagnosis: Can it be considered a warning sign?
Vijayasekharan K; Chatterjee G; Ramanathan S; Narula G; Tembhare P; Subramanian PG; Patkar N; Gujral S; Shetty D; Banavali S
Cytometry B Clin Cytom; 2021 May; 100(3):345-351. PubMed ID: 33030302
[TBL] [Abstract][Full Text] [Related]
8. Chronic myelogenous leukemia presenting in blast phase with nodal, bilineal myeloid sarcoma and T-lymphoblastic lymphoma in a child.
Chen X; Rutledge JC; Wu D; Fang M; Opheim KE; Xu M
Pediatr Dev Pathol; 2013; 16(2):91-6. PubMed ID: 23171293
[TBL] [Abstract][Full Text] [Related]
9. Lineage involvement by BCR/ABL in Ph+ lymphoblastic leukemias: chronic myelogenous leukemia presenting in lymphoid blast vs Ph+ acute lymphoblastic leukemia.
Anastasi J; Feng J; Dickstein JI; Le Beau MM; Rubin CM; Larson RA; Rowley JD; Vardiman JW
Leukemia; 1996 May; 10(5):795-802. PubMed ID: 8656674
[TBL] [Abstract][Full Text] [Related]
10. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome.
Druker BJ; Sawyers CL; Kantarjian H; Resta DJ; Reese SF; Ford JM; Capdeville R; Talpaz M
N Engl J Med; 2001 Apr; 344(14):1038-42. PubMed ID: 11287973
[TBL] [Abstract][Full Text] [Related]
11. Single-cell molecular analysis defines therapy response and immunophenotype of stem cell subpopulations in CML.
Warfvinge R; Geironson L; Sommarin MNE; Lang S; Karlsson C; Roschupkina T; Stenke L; Stentoft J; Olsson-Strömberg U; Hjorth-Hansen H; Mustjoki S; Soneji S; Richter J; Karlsson G
Blood; 2017 Apr; 129(17):2384-2394. PubMed ID: 28122740
[TBL] [Abstract][Full Text] [Related]
12. Bilineal Extramedullary Blast Crisis as an Initial Presentation of Chronic Myeloid Leukemia: A Case Report and Literature Review.
Gao X; Li J; Wang L; Lin J; Jin H; Xu Y; Wang N; Zhao Y; Liu D; Yu L; Wang Q
Am J Case Rep; 2016 Oct; 17():793-798. PubMed ID: 27784881
[TBL] [Abstract][Full Text] [Related]
13. Chronic myeloid leukaemia (CML) presenting in B-lymphoblastic crisis: a diagnostic challenge.
Xu K; Nacheva E
J Hematop; 2023 Dec; 16(4):243-245. PubMed ID: 38175430
[TBL] [Abstract][Full Text] [Related]
14. Prediction for sustained deep molecular response of BCR-ABL1 levels in patients with chronic myeloid leukemia in chronic phase.
Sasaki K; Kantarjian H; O'Brien S; Ravandi F; Konopleva M; Borthakur G; Garcia-Manero G; Wierda W; Daver N; Ferrajoli A; Takahashi K; Jain P; Rios MB; Pierce S; Jabbour E; Cortes JE
Cancer; 2018 Mar; 124(6):1160-1168. PubMed ID: 29266206
[TBL] [Abstract][Full Text] [Related]
15. Myeloid neoplasms with concurrent BCR-ABL1 and CBFB rearrangements: A series of 10 cases of a clinically aggressive neoplasm.
Salem A; Loghavi S; Tang G; Huh YO; Jabbour EJ; Kantarjian H; Wang W; Hu S; Luthra R; Medeiros LJ; Khoury JD
Am J Hematol; 2017 Jun; 92(6):520-528. PubMed ID: 28253536
[TBL] [Abstract][Full Text] [Related]
16. Prominent hematogone hyperplasia in BCR-ABL1-positive chronic myelogenous leukemia: mimicking recurrent B-lymphoid blast crisis.
Horna P; Pantazopoulos P; Lancet JE; Moscinski LC; Zhang L
Leuk Lymphoma; 2014 Aug; 55(8):1952-4. PubMed ID: 24304373
[No Abstract] [Full Text] [Related]
17. The receptor tyrosine kinase p185HER2 is expressed on a subset of B-lymphoid blasts from patients with acute lymphoblastic leukemia and chronic myelogenous leukemia.
Bühring HJ; Sures I; Jallal B; Weiss FU; Busch FW; Ludwig WD; Handgretinger R; Waller HD; Ullrich A
Blood; 1995 Sep; 86(5):1916-23. PubMed ID: 7544646
[TBL] [Abstract][Full Text] [Related]
18. Clinical Efficacy and Safety of First-Line Dasatinib Therapy and the Relevance of Velocity of BCR-ABL1 Transcript Decline for Achievement of Molecular Responses in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia: Report from the Juntendo Yamanashi Cooperative Study Group.
Takaku T; Iriyama N; Mitsumori T; Sato E; Gotoh A; Kirito K; Noguchi M; Koike M; Sakamoto J; Oba K; Komatsu N
Oncology; 2018; 94(2):85-91. PubMed ID: 29151104
[TBL] [Abstract][Full Text] [Related]
19. Differentiation status of primary chronic myeloid leukemia cells affects sensitivity to BCR-ABL1 inhibitors.
Pietarinen PO; Eide CA; Ayuda-Durán P; Potdar S; Kuusanmäki H; Andersson EI; Mpindi JP; Pemovska T; Kontro M; Heckman CA; Kallioniemi O; Wennerberg K; Hjorth-Hansen H; Druker BJ; Enserink JM; Tyner JW; Mustjoki S; Porkka K
Oncotarget; 2017 Apr; 8(14):22606-22615. PubMed ID: 28186983
[TBL] [Abstract][Full Text] [Related]
20. [Immunophenotypic features of bcr/abl fusion transcript-positive B-lineage acute lymphoblast leukemia].
Li JL; Liu YR; Qin YZ; Chang Y; Fu JY; Wang H; Ruan GR; Chen SS
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2003 Apr; 11(2):142-5. PubMed ID: 12744735
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
